Gentiva Health Services (Nasdaq: GTIV) is expected to report Q2 earnings around July 20. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Gentiva Health Services' revenues will drop -4.7% and EPS will wither -42.9%.

The average estimate for revenue is $435.4 million. On the bottom line, the average EPS estimate is $0.28.

Revenue details
Last quarter, Gentiva Health Services reported revenue of $435.7 million. GAAP reported sales were 3.4% lower than the prior-year quarter's $451.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.24. GAAP EPS of $0.16 for Q1 were 63% lower than the prior-year quarter's $0.43 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 46.5%, 230 basis points worse than the prior-year quarter. Operating margin was 7.9%, 350 basis points worse than the prior-year quarter. Net margin was 1.1%, 190 basis points worse than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $1.75 billion. The average EPS estimate is $1.14.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 294 members rating the stock outperform, and 17 members rating it underperform. Among 96 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 91 give Gentiva Health Services a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Gentiva Health Services is hold, with an average price target of $7.40.